Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dental Pulp MSCs for Severe COVID-19 Pneumonia
NCT04302519Phase 1Unknown
- Sponsor
- CARsgen Therapeutics
- Start
- Mar 2020
- Primary completion
- Jun 2021
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of dental pulp mesenchymal stem cells in coronavirus disease 2019 (COVID-19), sponsored by CARsgen Therapeutics. Primary endpoint: Disppear time of ground-glass shadow in the lungs at 14 days. Status: unknown.
02
Drugs
dental pulp mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04302519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04302519.